Skip to main content
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Obesity Studies

Metabolic Endotoxemia Initiates Obesity and Insulin Resistance

  1. Patrice D. Cani12,
  2. Jacques Amar3,
  3. Miguel Angel Iglesias1,
  4. Marjorie Poggi4,
  5. Claude Knauf1,
  6. Delphine Bastelica4,
  7. Audrey M. Neyrinck2,
  8. Francesca Fava5,
  9. Kieran M. Tuohy5,
  10. Chantal Chabo1,
  11. Aurélie Waget1,
  12. Evelyne Delmée2,
  13. Béatrice Cousin6,
  14. Thierry Sulpice7,
  15. Bernard Chamontin3,
  16. Jean Ferrières3,
  17. Jean-François Tanti8,
  18. Glenn R. Gibson5,
  19. Louis Casteilla6,
  20. Nathalie M. Delzenne2,
  21. Marie Christine Alessi4 and
  22. Rémy Burcelin1
  1. 1Institute of Molecular Medicine, I2MR Toulouse, France
  2. 2Unité Pharmacokinetics, Metabolism, Nutrition, and Toxicology-73/69, Université catholique de Louvain, Brussels, Belgium
  3. 3Institut National de la Santé et de la Recherche Médicale (INSERM) 558, Toulouse, France
  4. 4INSERM U 626, Marseille, France
  5. 5Food Microbial Sciences Unit, Department of Food Biosciences, University of Reading, Reading, U.K
  6. 6Unité Mixte de Recherche 5241, Centre National de la Recherche Scientifique, Université Paul Sabatier, Toulouse, France
  7. 7Physiogenex S.A.S., Labège Innopole, France
  8. 8INSERM U 568, Nice, France
  1. Address correspondence and reprint requests to Rémy Burcelin, I2MR U858, IFR 31, Hôpital Rangueil, BP 84225, Toulouse 31432 Cedex 4, France. E-mail: burcelin{at}toulouse.inserm.fr
Diabetes 2007 Jul; 56(7): 1761-1772. https://doi.org/10.2337/db06-1491
PreviousNext
  • Article
  • Figures & Tables
  • Info & Metrics
  • PDF
Loading

Article Figures & Tables

Figures

  • FIG. 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIG. 1.

    High-fat feeding increased endotoxemia and changed intestinal microbiota. A: Plasma LPS concentration (EU/ml) was assessed every 4 h throughout the day in normal diet (CT; n = 9) (▪) and 4-week high-fat–fed (HF; n = 9) (○) mice. B: Groups of bacteria in the caecal content of mice fed the normal diet (CT; n = 8) or the high-fat diet (HF; n = 8) for 4 weeks. Bacterial numbers are expressed as log10 (bacterial cells per gram caecal content wet weight). *P < 0.05 vs. CT. C: Delta plasma LPS concentration in (EU/ml) in mice before and 30 min after an oral administration of LPS diluted in corn oil (n = 6) (oil-LPS) or in water (n = 6) (H2O-LPS) or an administration of oil alone (n = 6) (oil). *P < 0.05 vs. H2O-LPS. Data are means ± SE.

  • FIG. 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIG. 2.

    Chronic experimental metabolic endotoxemia induces obesity and diabetes. A: Plasma endotoxin concentration (EU/ml) in WT mice infused with saline (CT; n = 18) or LPS (n = 18) for 4 weeks using subcutaneous osmotic pumps and compared with mice fed a high-fat diet for 4 weeks (HF; n = 18). B: Plasma glucose (mmol/l) following an oral glucose load (3 g/kg) in control (CT; n = 24), LPS (n = 13), or high-fat diet (HF; n = 24) mice. The inset represents the area under curve for each group. *P < 0.05 vs. CT; §LPS vs. CT; #HF vs. LPS. C: Plasma insulin (pmol/l) concentrations 30 min before (−30) and 15 min after (15) an oral glucose load in control (CT; n = 24), LPS (n = 13), or high-fat diet–fed (HF; n = 24) mice. D: Hepatic glucose production and whole-body glucose turnover rates (mg · kg−1 · min−1) in control (CT; n = 5), LPS (n = 5), or high-fat diet–fed (HF; n = 5) mice. E: Body weight (g) before (day 0) and after a 28-day treatment period (day 28) and body weight gain (Δ) in control (CT; n = 26), LPS (n = 21), or high-fat diet–fed (HF; n = 34) mice. F: Visceral and subcutaneous adipose tissue weight (percentage of body weight) in control (CT; n = 26), LPS (n = 21), or high-fat diet–fed (HF; n = 34) mice. G: Liver weight (percentage of body weight) in control (CT; n = 26), LPS (n = 21), or high-fat diet–fed (HF; n = 34) mice. H: Liver triglycerides (μmol/liver) in control (CT; n = 12), LPS (n = 9), or high-fat diet–fed (HF; n = 11) mice. I: Mean energy intake (kcal · day−1 · mouse−1) in control (CT; n = 18), LPS (n = 18), or high-fat diet–fed (HF; n = 18) mice. Data are means ± SE. Data with different superscript letters are significantly different at P < 0.05, according to the post hoc ANOVA statistical analysis.

  • FIG. 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIG. 3.

    Metabolic endotoxemia triggers the expression of inflammatory factors similarly to high-fat feeding. TNF-α, IL-1, IL-6, and PAI-1 mRNA concentrations (A, E, and I) in liver (B, F, and J), visceral adipose tissue (C, G, and K), subcutaneous adipose tissue (D, H, and L), and muscle in normal diet–fed (n = 8) (□) or high-fat diet–fed (n = 8) (▪) mice for 2 weeks (A–D) and 4 weeks (n = 8) (E–H) and in LPS-infused mice (n = 5) (I–L). Data are means ± SE. *P < 0.05 vs. normal chow–fed mice.

  • FIG. 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIG. 4.

    CD14 mutant mice are protected against LPS-induced inflammation. mRNA concentrations of IL-6, PAI-1, and IL-1 in adipose tissue 3 h after a saline (control [CT]; n = 6) or an LPS (n = 6) infusion in WT (A) and CD14 mutant (B) mice. *P < 0.05 vs. CT; §P < 0.05 vs. WT. C: Representative Western blot analysis of p-NFk-B and p-IKK-b and p-IKK-a in the liver of mice from the same experiment. Protein Ct corresponds to a loading control of major protein, which cross-reacts nonspecifically with the anti–p-IKK-a antibody.

  • FIG. 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIG. 5.

    The CD14 null mutation prevents the effect of LPS-induced obesity and diabetes. A: Body weight gain (g) in WT mice infused with saline (WT-CT; n = 13) or LPS (WT-LPS; n = 14) and CD14 mutant mice infused with saline (CD14-CT; n = 13) or LPS (CD14-LPS; n = 12) for 4 weeks using subcutaneous osmotic pumps. B: Visceral and subcutaneous adipose tissue weight (percentage of body weight) in WT-CT (n = 13) (□), WT-LPS (n = 14) (▪), CD14-CT (n = 13) (▒), and CD14-LPS (n = 12) (Embedded Image) mice. C: Plasma glucose concentration (mmol/l) following an intraperitoneal glucose load (1 g/kg) in WT-CT (n = 6) (▪), WT-LPS (n = 6) (▴), CD14-CT (n = 5) (□), and CD14-LPS (n = 6) (•) mice. The inset represents the area under curve of the same groups. D: Plasma insulin (pmol/l) concentration 30 min before (−30) and 30 min after (30) intraperitoneal glucose administration in WT-CT (n = 6) (□), WT-LPS (n = 6) (▪), CD14-CT (n = 5) (Embedded Image), and CD14-LPS (n = 6) (▒) mice. E: Liver weight (percentage of body weight) in WT-CT (n = 13), WT-LPS (n = 13), CD14-CT (n = 12), and CD14-LPS (n = 13) mice. F: Liver triglycerides (μmol/liver) in WT-CT (n = 12), WT-LPS (n = 9), CD14-CT (n = 5), and CD14-LPS (n = 6) mice. Data are means ± SE. Data with different superscript letters are significantly different at P < 0.05, according to the post hoc ANOVA statistical analysis.

    • Download figure
    • Open in new tab
    • Download powerpoint
    • Download figure
    • Open in new tab
    • Download powerpoint
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIG. 6.

    CD14: the main LPS receptor sets the tone of insulin sensitivity and hepatic steatosis. A: Glucose turnover (mg · kg−1 · min−1) in WT mice or CD14 mutant fed a normal diet (CT) or fed a high-fat diet (HF) for 4 (n = 8) or 24 (n = 8) weeks (wks). B: Body weight gain (g) in WT or CD14 mutant fed a normal diet (CT) for 4 (n = 8) or 24 (n = 8) weeks or fed a high-fat diet (HF) for 4 (n = 8) or 24 (n = 8) weeks. C: Liver weight (percent of body weight) in WT or CD14 mutant mice fed a normal diet (CT) for 4 (n = 8) or 24 (n = 8) weeks or fed a high-fat diet (HF) for 4 (n = 8) or 24 (n = 8) weeks. D: Liver triglycerides (μmol/liver) in WT or CD14 mutant mice fed a normal diet (CT) for 4 (n = 6) or 24 (n = 5) weeks or fed a high-fat diet (HF) for 4 (n = 5) or 24 (n = 5) weeks. Data are means ± SE. *P < 0.05 vs. CT; §P < 0.05 vs. WT. E: Representative oil red O liver staining in 4-week–treated mice. F (see next page): Plasma glucose following an intraperitoneal glucose load (1 g/kg) in WT mice fed a normal diet (WT-CT; n = 8) or a high-fat diet (WT-HF; n = 8) for 24 weeks and CD14 mutant mice fed a normal diet (CD14-CT; n = 8) or fed a high-fat diet (CD14-HF; n = 8). The inset represents the area under curve of the same groups. G (see next page): Fasting plasma insulin (pmol/l) in WT or CD14 mutant mice fed a normal diet (CT) for 4 (n = 6) or 24 (n = 5) weeks or fed a high-fat diet (HF) for 4 (n = 5) or 24 (n = 5) weeks. Data are means ± SE. *P < 0.05 vs. CT; §P < 0.05 vs. WT. Data with different superscript letters are significantly different at P < 0.05, according to the post hoc ANOVA statistical analysis.

  • FIG. 7.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIG. 7.

    CD14 mutant mice resist high-fat diet–induced glucose intolerance, inflammation, and increased visceral fat mass. A: Plasma glucose (mmol/l) following an intraperitoneal glucose load (1 g/kg) in WT mice fed a normal diet (WT-CT; n = 6) (▪) or a high-fat diet (WT-HF; n = 6) (▴) for 4 weeks and CD14 mutant mice fed a normal diet (CD14-CT; n = 5) (•) or fed a high-fat diet (CD14-HF; n = 5) (□). The inset represents the area under curve of the same groups. B: Plasma insulin concentration (pmol/l) 30 min before (−30) and 30 min after (30) intraperitoneal glucose administration in WT-CT (n = 6) (□), WT-HF (n = 6) (▪), CD14-CT (n = 5) ( ▒), and CD14-HF (n = 5) (Embedded Image) mice. C: Visceral and subcutaneous adipose tissue weight (percent of body weight) in WT-CT (n = 6) (□), WT-HF (n = 6) (▪), CD14-CT (n = 5) (▒), and CD14-HF (n = 5) (Embedded Image) mice. Adipose tissue (D) and liver (E) mRNA concentrations of TNF-α, IL-1, IL-6, and PAI-1 in WT-CT (n = 6) (□), WT-HF (n = 6) (▪), CD14-CT (n = 5) (▒), and CD14-HF (n = 5) (Embedded Image) mice. Data are means ± SE. Data with different superscript letters are significantly different at P < 0.05, according to the post hoc ANOVA statistical analysis.

    • Download figure
    • Open in new tab
    • Download powerpoint
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIG. 8.

    Metabolic endotoxemia impairs adipocyte morphology. A: Adipocyte size distribution (%) in WT mice fed a normal diet (WT-CT; n = 765) (□) or a high-fat diet (WT-HF; n = 661) (▪) for 4 weeks or CD14 mutant mice fed a normal diet (CD14-CT; n = 1,032) ( ▒) or a high-fat diet (CD14-HF; n = 729) (Embedded Image) for 4 weeks. B: Adipocyte size distribution (%) in WT mice infused with saline (WT-CT; n = 765) (□) or LPS (WT-LPS; n = 750) (▪) and CD14 mutant mice infused with saline (CD14-CT; n = 1,032) (▒) or LPS (CD14-LPS; n = 585) (Embedded Image) for 4 weeks using subcutaneous osmotic pumps. C: Adipocyte mean area (μm2) in WT-CT (n = 765), WT-HF (n = 661), WT-LPS (n = 750), CD14-CT (n = 1,032), CD14-HF (n = 729), or CD14-LPS (n = 585) mice. D: Representative adipose tissue staining in 4-week–treated mice. E: F4/80-positive cells (+ cells/total cells) of all above groups. Data are means ± SE. Data with different superscript letters are significantly different at P < 0.05, according to the post hoc ANOVA statistical analysis.

PreviousNext
Back to top

In this Issue

July 2007, 56(7)
  • Table of Contents
  • Index by Author
Sign up to receive current issue alerts
View Selected Citations (0)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Metabolic Endotoxemia Initiates Obesity and Insulin Resistance
(Your Name) has forwarded a page to you from Diabetes
(Your Name) thought you would like to see this page from the Diabetes web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Metabolic Endotoxemia Initiates Obesity and Insulin Resistance
Patrice D. Cani, Jacques Amar, Miguel Angel Iglesias, Marjorie Poggi, Claude Knauf, Delphine Bastelica, Audrey M. Neyrinck, Francesca Fava, Kieran M. Tuohy, Chantal Chabo, Aurélie Waget, Evelyne Delmée, Béatrice Cousin, Thierry Sulpice, Bernard Chamontin, Jean Ferrières, Jean-François Tanti, Glenn R. Gibson, Louis Casteilla, Nathalie M. Delzenne, Marie Christine Alessi, Rémy Burcelin
Diabetes Jul 2007, 56 (7) 1761-1772; DOI: 10.2337/db06-1491

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

Metabolic Endotoxemia Initiates Obesity and Insulin Resistance
Patrice D. Cani, Jacques Amar, Miguel Angel Iglesias, Marjorie Poggi, Claude Knauf, Delphine Bastelica, Audrey M. Neyrinck, Francesca Fava, Kieran M. Tuohy, Chantal Chabo, Aurélie Waget, Evelyne Delmée, Béatrice Cousin, Thierry Sulpice, Bernard Chamontin, Jean Ferrières, Jean-François Tanti, Glenn R. Gibson, Louis Casteilla, Nathalie M. Delzenne, Marie Christine Alessi, Rémy Burcelin
Diabetes Jul 2007, 56 (7) 1761-1772; DOI: 10.2337/db06-1491
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • RESEARCH DESIGN AND METHODS
    • RESULTS
    • DISCUSSION
    • Acknowledgments
    • Footnotes
    • REFERENCES
  • Figures & Tables
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Deficiency of Stat1 in CD11c+ Cells Alters Adipose Tissue Inflammation and Improves Metabolic Dysfunctions in Mice Fed a High-Fat Diet
  • Placental Insulin/IGF-1 Signaling, PGC-1α, and Inflammatory Pathways Are Associated With Metabolic Outcomes at 4–6 Years of Age: The ECHO Healthy Start Cohort
  • Defective FXR-SHP Regulation in Obesity Aberrantly Increases miR-802 Expression, Promoting Insulin Resistance and Fatty Liver
Show more Obesity Studies

Similar Articles

Navigate

  • Current Issue
  • Online Ahead of Print
  • Scientific Sessions Abstracts
  • Collections
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes Care
  • Clinical Diabetes
  • Diabetes Spectrum
  • Scientific Sessions Abstracts
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2021 by the American Diabetes Association. Diabetes Print ISSN: 0012-1797, Online ISSN: 1939-327X.